Abstract The US Food and Drug administration (FDA) has approved several polyclonal
antibody preparations and at least 18 monoclonal antibody preparations (antibodies …

Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs such
as octreotide is an effective therapy against neuroendocrine tumors. Other radiolabeled …

Immune checkpoint inhibitors (ICIs), by reinvigorating CD8+ T cell mediated immunity, have
revolutionized cancer therapy. Yet, the systemic CD8+ T cell distribution, a potential …

Idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in
development as a specific antidote for dabigatran. In this first-in-human, single-rising-dose …

Gadolinium-based MRI contrast agents (CAs) can be effective at a∼ 100-fold lower
concentration of Gadolinium ions in comparison to the concentration of Iodine atoms …

As scintigraphy with [111 In-DTPA 0] octreotide has become a standard technique in
analysing somatostatin receptor-receptor positive lesions such as neuroendocrine tumours …

New peptide-based probes to facilitate the molecular imaging of disease are rapidly
evolving due to implementation of combinatorial chemistry and bacteriophage (phage) …

Elevated renal uptake and prolonged retention of radiolabeled antibody fragments and
peptides is a problem in the therapeutic application of such agents. Over recent years, one …

Only a handful of radiolabeled antibodies (Abs) have gained US Food and Drug
Administration (FDA) approval for use in clinical oncology, including four immunodiagnostic …

Molecular imaging is paving the way towards noninvasive detection, staging, and treatment
follow-up of diseases such as cancer and inflammation-related conditions. Monoclonal …